Fig 5. Effect of short-course or delayed-course CD47 blockade on micrometastatic pancreatic ductal adenocarcinoma (PDAC) tumor burden.

A) Evaluation of short-course αCD47 antibody treatment. Dot plots of tumor burden at 58 days post-splenic injection following daily therapy from days 2-22 with a blocking anti-CD47 antibody (αCD47, blue), purified IgG from mouse serum (Mouse IgG, red), or no treatment (black) in mice bearing T608 (n = 11-12 per group). The dotted line represents a relative hepatic tumor burden of 2.0, defined as disease progression. Data are expressed as median ± interquartile range. Kruskal-Wallis test with Dunn’s test for multiple comparisons was used to compare tumor burdens. Significance is denoted as * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. B) Effect of delayed-course αCD47 antibody treatment. Growth curves of hepatic tumor burden relative to 15 days post-splenic injection in mice bearing T608 which received daily therapy with a blocking anti-CD47 antibody (αCD47, blue), purified IgG from mouse serum (Mouse IgG, red), or no treatment (black) from days 15-35 (n = 11-12 per group). Tumor burden at 78 days was significantly lower in mice treated with αCD47 (no treatment vs Mouse IgG: p=0.99, no treatment vs αCD47: p=0.004, Mouse IgG vs αCD47: p=0.006). Data are expressed as median ± interquartile range. The dotted line represents a relative hepatic tumor burden of 1.0. Kruskal-Wallis test with Dunn’s test for multiple comparisons was used to compare tumor burdens.